OBJECTIVE:: As glucagon-like peptide-1 receptor agonists lower blood pressure (BP) in type 2 diabetes mellitus (T2DM), we examined BP control in relation to targets set by international bodies prior to randomization in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial. METHODS:: We analyzed baseline data from LEADER (NCT01179048), an ongoing phase 3B, randomized, double-blind, placebo-controlled cardiovascular outcomes trial examining the cardiovascular safety of the glucagon-like peptide-1 receptor agonist liraglutide in 9340 people with T2DM from 32 countries [age (all mean?±?SD) 64?±?7.2 years, BMI 32.5?±?6.3?kg/m, duration of diabetes 12.7?±?8.0 years], all of whom were at high risk for cardiovascular disease (CVD). RESULTS:: A total of 81% (n?=?7592) of participants had prior CVD and 90% (n?=?8408) had a prior history of hypertension. Despite prescription of multiple antihypertensive agents at baseline, only 51% were treated to a target BP of less than 140/85?mmHg and only 26% to the recommended baseline BP target of less than 130/80?mmHg. In univariate analyses, those with prior CVD were prescribed more agents (P?
ASJC Scopus subject areas
- Internal Medicine
- Cardiology and Cardiovascular Medicine